Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

491.41 +1.02 (+0.21%)

Streaming Delayed Price Updated: 9:50 AM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

67 68 Next >

Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗

Today 6:10 EDT

Via Chartmill

3 Healthcare Stocks with Competitive Advantages

July 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗

July 21, 2026

Via Chartmill

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗

July 19, 2026

The biotech's diversification efforts continue.

Via The Motley Fool

Topics Intellectual Property

1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question

July 16, 2026

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...

Via StockStory

Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗

June 23, 2026

Via Chartmill

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

July 15, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals...

Via Benzinga

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗

July 14, 2026

Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.

Via The Motley Fool

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗

July 13, 2026

Vertex Pharmaceuticals recently announced its largest-ever acquisition.

Via The Motley Fool

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗

July 11, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a...

Via MarketBeat

Is This Biotech Stock a Buy Near Its 52-Week High? ↗

July 10, 2026

It's been a volatile year for the company, but don't let that scare you away.

Via The Motley Fool

Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗

July 10, 2026

It is getting acquired by a larger firm in the sector.

Via The Motley Fool

Topics Bonds

3 Reasons to Buy CRISPR Therapeutics Stock ↗

July 10, 2026

The company's innovative qualities may pay rich dividends down the road.

Via The Motley Fool

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗

July 10, 2026

Additional blockbuster drugs may be on the horizon.

Via The Motley Fool

Topics Intellectual Property

1 Momentum Stock to Research Further and 2 Facing Headwinds

July 09, 2026

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a...

Via StockStory

Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗

July 08, 2026

Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis...

Via MarketBeat

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗

July 08, 2026

This new technology could one day significantly expand the market for gene-editing biotechs.

Via The Motley Fool

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗

July 08, 2026

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Via The Motley Fool

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗

July 07, 2026

The drugmaker is paying up for a new growth engine. Is the price disciplined?

Via The Motley Fool

Topics Intellectual Property

3 Cash-Heavy Stocks with Promising Prospects

July 07, 2026

In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for t...

Via StockStory

Which S&P500 stocks are showing activity after the closing bell on Monday? ↗

July 06, 2026

Via Chartmill

Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗

July 06, 2026

The pharma stock is up around 17% this year.

Via The Motley Fool

While SpaceX Gets the Headlines, Smart Investors Are Loading Up on This Stock Instead ↗

July 05, 2026

This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗

July 03, 2026

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

Via The Motley Fool

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026? ↗

July 01, 2026

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?

Via The Motley Fool

Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)

June 29, 2026

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers. ...

Via StockStory

Topics Artificial Intelligence

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

June 29, 2026

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on an annualized basis producing an average annual return of 19.73%. Currently, Vertex Pharmaceuticals...

Via Benzinga

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 27, 2026

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Via The Motley Fool

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗

June 23, 2026

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Via MarketBeat

Topics ETFs

The Best Stocks to Invest $1,000 in Right Now ↗

June 22, 2026

Exploring some of the top bargains in a multi-trillion-dollar industry.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

67 68 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.